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Abstract
Background: Many studies associated nosocomial infections with increased hospital costs due to
extra days in hospital, staff time, extra investigations and drug treatment. The cost of antibiotic
treatment for these infections represents a significant part of hospital expenditure. This
prospective observational study was designed to determine the daily antibiotic cost of nosocomial
infections per infected adult patient in Akdeniz University Hospital.
Methods: All adult patients admitted to the ICUs between January 1, 2000, and June 30, 2003 who
had only one nosocomial infection during their stay were included in the study. Infection sites and
pathogens, antimicrobial treatment of patient and it's cost were recorded. Daily antibiotic costs
were calculated per infected patient.
Results: Among the 8460 study patients, 817 (16.6%) developed 1407 episodes of nosocomial
infection. Two hundred thirty three (2.7%) presented with only one nosocomial infection. Mean
daily antibiotic cost was $89.64. Daily antibiotic cost was $99.02 for pneumonia, $94.32 for
bloodstream infection, $94.31 for surgical site infection, $52.37 for urinary tract infection, and
$162.35 for the other infections per patient. The treatment of Pseudomonas aeruginosa infections
was the most expensive infection treated. Piperacillin-tazobactam and amikacin were the most
prescribed antibiotics, and meropenem was the most expensive drug for treatment of the
nosocomial infections in the ICU.
Conclusions: Daily antibiotic cost of nosocomial infections is an important part of extra costs that
should be reduced providing rational antibiotic usage in hospitals.
Background
Nosocomial infections are frequent complications of hos-
pitalization and also an important public health problem
in developing countries, as well as in developed ones. The
socioeconomic impact, ie, prolongation of hospitaliza-
tion, mortality, and cost of these infections adversely
effects patients and nations' economic well-being [1]. The
cost of nosocomial infections includes increased length of
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hospital stay, staff time, laboratory cultures of pathogens
and antimicrobial treatment [2-4]. Although, cost of anti-
microbial treatment is an important part of health
expenditure, data on this subject are extremely limited in
Turkey.
The aim of our study was to determine daily antibiotic
cost of nosocomial infection per infected patient in a uni-
versity hospital.
Methods
The hospital setting
Akdeniz University Hospital is a 600-bed tertiary referral
centre in Antalya, Turkey, treating 27 000 patients per
year. The study was conducted in six adult medical and
surgical intensive care units (ICUs) with a total of 51 ICU
beds. Neonatal ICU was not included in the study. Since
1993, the institutional policies of hospital infection con-
trol have been implemented by infection control team.
Definitions and study population
In our hospital, routine prospective, active surveillance of
nosocomial infections in all ICUs is performed by one
infection control nurse, supervised by an infection control
physician. Nosocomial infections are defined using the
Centers for Disease Control and Prevention criteria [5,6].
We do not follow patients for signs of infection after dis-
charge unless they are readmitted to the hospital.
Between January 1, 2000 and June 30, 2003, all inpatients
hospitalized in one of the adult ICUs were included in this
study. Data on antimicrobial treatment were recorded for
patients aged 15 or above presenting with only one noso-
comial infection. For all patients included in the study,
the following were recorded: age, sex, infection site,
microbiologic data, antimicrobial therapy and antibiotic
cost.
Measurement of costs
In our ICUs, all antimicrobial prescriptions are recom-
mended by an infectious disease consultant. Antimicro-
bial agents prescribed only for therapeutic indications
were recorded. The daily antibiotic cost was calculated in
US dollars based on June 2003 prices of antimicrobial
agents provided by the hospital pharmacy. The daily anti-
biotic cost per infected patient was calculated by the mul-
tiplication of box price and number of daily doses that
was used for that infection. Two costs were calculated for
each antimicrobial; the minimal cost (min) was based on
the lowest recommended parenteral daily dose and the
maximal cost (max) was based on the highest recom-
mended parenteral daily dose.
Results
Between January 1, 2000, and June 30, 2003, a total of
8460 patients were admitted to the adult ICUs. Overall,
817 patients developed 1407 episodes of nosocomial
infections, accounting for an infection rate of 16,6%.
Among them, 233 patients (mean age:50,1; sex ratio
female:male 0,49) had only one nosocomial infection.
Mean daily antibiotic cost was found $89,64 per infected
patient ($8,56 to $359,28).
Among the sites of nosocomial infections, urinary tract
infections had the lowest daily antibiotic cost per infected
patient (Table 1). The mean daily antibiotic cost for pneu-
monia was the highest of all sites, but patients with blood-
stream infection reached the highest range of daily cost
($31,31 to $359,28). In addition, mean daily antibiotic
cost was found $162,35 for seventeen other infections
including postoperative meningitis, mediastinitis, and
empyema.
Out of 233 patients, 206 patients had microbiologically
documented infections, 177 patients were infected by a
single pathogen while 29 patients were diagnosed as hav-
ing polymicrobial infections (Table 2). Pseudomonas aeru-
ginosa  was the most prevalent bacteria followed by
Klebsiella spp. and Acinetobacter spp.. P. aeruginosa infec-
tions had the highest overall daily antibiotic cost per
infected patient than other pathogens. Among 21 Staphy-
lococcus aureus strains 15 (72%) were resistant to methicil-
lin. The overall daily antibiotic cost of methicillin
resistant S. aureus (MRSA) infections was two to three
times higher than infections with susceptible strains.
However, median daily cost per infected patient for MRSA
infections were lower than susceptible strain infections.
Table 1: Daily antibiotic costs according to the sites of nosocomial infections.
Site of nosocomial infections Number of patients Range of daily cost per infected (US$) Mean (US$)
Pneumonia 111 10,02–250,74 99,02
Bloodstream infections 28 31,31–359,28 94,32
Surgical site infections 11 17,12–204,74 94,31
Urinary tract infections 66 8,56–228,68 52,37BMC Infectious Diseases 2005, 5:5 http://www.biomedcentral.com/1471-2334/5/5
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Among the 350 antibiotic prescriptions for nosocomial
infections, piperacillin-tazobactam and amikacin were
the most prescribed antibiotics (Table 3). Carbapenems
especially meropenem were the most expensive drugs.
Disscussion
Cost is an important factor which determines the physi-
cian's choice of medication to treat patients in spesific
stiuations. In this study, we tried to demonstrate the daily
cost of antimicrobial treatment of nosocomial infections
according to site of infection, pathogen and antimicrobial
agent.
In different studies, economical analysis regarding costs
attributable to nosocomial infections has been evaluated
and reported between $1018 to 2280 per infected patient
[7-9]. Jarvis et al reported that the estimated average costs
of nosocomial infections were $558 to 593 for each uri-
nary tract infection, $2734 for each surgical site infection,
$3061 to 40000 for each bloodstream infection, and
$4947 for each pneumonia [1].
Daily cost of antimicrobial treatment has been reported to
be a significant extra cost attributable to nosocomial
infections. In this study, we found an average daily antibi-
otic cost of $89,64 per nosocomial infection. It is clear
that cost of overall antibiotic treatment for a period of
approximately 10–15 days is $900 to $1350. Prolonga-
tion of hospital stay has been the major extra cost attrib-
utable to nosocomial infections in many reports [2-4], but
in comparative case-control study from our country,
Yalcin et al. [8] found that cost of antibiotic therapy of
$1190 per infected patient, accounted for about 75% of
the total extra cost. This finding may be due to the high
prices of antibiotics in Turkey. To calculate the true costs
of antibiotic therapy, hidden costs arising from intrave-
nous administration, labor, serum antibiotic assay, mon-
itoring hematological and biochemical indices and
adverse effects of antibiotics must be considered [10]. The
present study does not include these relevant "hidden
costs" that could substantially modify the total cost of an
antibiotic treatment. Although, hidden costs were not cal-
culated, an average daily antibiotic cost of a single noso-
comial infection is found to be markedly high in our
hospital.
This result is within the limits reported by other large eco-
nomic studies, suggesting that our data is comparable to
those found in other countries and with other assessment
methods. In a French prevalence survey, Astagneau et
al.[11] reported an average daily antibiotic cost between
FF 520 to 1085 (about $86 to $160) per nosocomial infec-
tion. French et al.[12] and Haley et al.[13] reported an
average cost of antibiotic treatment of $190 and between
$72 to $128 per nosocomial infection, respectively. In
Table 2: Daily antibiotic cost according to the pathogens.
Pathogens No. Overall daily cost (US$) Range of daily cost per pathogen (US$) Median (US$)
Pseudomonas aeruginosa 60 5567,06 17,98–204,74 100,04
Acinetobacter spp 36 4951,06 17,98–359,28 92,47
Stenotrophomonas 
maltophilia
4 310,99 31,31–100,04 89,82
Klebsiella spp 37 3104,22 10,02–179,64 79,6
Enterobacter spp 10 961,79 60,42–139,08 77,28
Escherichia coli 23 1652,57 10,02–179,64 60,41
Proteus spp 3 49,04 13,24–49,04 49,04
Staphylococcus aureus
Methicillin-susceptible (MS) 6 476,22 10,02–142,2 74,52
Methicillin-resistance (MR) 15 1188,1 35,88–142,2 71,1
CoNS*
MS-CoNS 1 49,64 16,34–49,64 49,64
MR-CoNS 3 148,92 17,52–49,64 49,64
Enterococcus spp 16 1141,25 32,29–142,2 49,64
Candida spp 21 235,52 8,56–38,64 8,56
No pathogen identified 27 3166,75 10,02–359,28 114,6
* Coagulase negative StaphylococcusBMC Infectious Diseases 2005, 5:5 http://www.biomedcentral.com/1471-2334/5/5
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Table 3: Daily cost of antimicrobial agents for nosocomial infections.
Antimicrobial agents Number of prescriptions Daily cost per infected (US$)
Min Max
Betalactams
Ampicillin-sulbactam 20 23,92 71,76
Piperacillin-tazobactam 48 85,95 114,6
Ticarcillin-clavulanate 4 14,9 22,35
Carbapenems
Imipenem 31 100,04 150,06
Meropenem 23 179,64 359,28
Cephalosporins
Cefepime 26 38,64 77,28
Ceftazidime 18 35,82 71,64
Cefoperazone-sulbactam 16 40,28 80,56
Cefazoline 10 10,02 20,04
Ceftriaxone 3 19,7 39,4
Aminoglycosides*
Amikacin 52 - 7,96
Netilmicin 21 - 24,48
Tobramycin 3 - 18,56
Fluoroquinolones
Ciprofloxacin 18 49,04 98,08
Ofloxacin 2 25,74 51,48
Levofloxacin 1 41,07 82,14
Glycopeptides
Vancomycin 13 49,64 87,27
Teicoplanin 12 71,1 142,2
Other antibiotics
Clarithromycin 4 11,57 23,14
Trimethoprim-
sulphamethoxazole
2 4,48 8,96
Metronidazole 2 5,51 10,04
Antifungal agents
Fluconazole 21 8,56 34,24
Total 350 8,56 359,28
* dosage given as once-daily.BMC Infectious Diseases 2005, 5:5 http://www.biomedcentral.com/1471-2334/5/5
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Turkey, Yalcin et al.[14] found that daily antibiotic cost of
nosocomial infections was $70 per patient.
The daily antibiotic cost varies markedly according to site
of infection. Our study has demonstrated that pneumonia
and bloodstream infections were associated with the high-
est daily antibiotic costs as reported in other studies
[11,13,14]. Surgical site infections had also high daily
antibiotic cost in our study. In their case-control study,
Coello et al. reported that antibiotic therapy for surgical
patients was the second most significant contributor to
cost [15]. In the present study, nosocomially infected
patients that had only one nosocomial infection were
considered for analysis. Clearly, antimicrobial treatment
of patients with multiple nosocomial infections might be
much more expensive.
P. aeruginosa infections had the highest daily antibiotic
cost followed by other non-fermentative bacilli. Infec-
tions caused by P. aeruginosa are difficult to treat because
of its virulence and relatively limited choice of effective
antimicrobial agents, so, these infections often require
combination therapy. Emergence of resistance in P. aeru-
ginosa has been associated with increased morbidity, mor-
tality, and costs [16]. On the other hand, although the
overall antibiotic cost of MRSA infections was higher than
infections with susceptible strains, the daily antibiotic
cost per infected patient with MRSA was lower with sus-
ceptible strain infections. MRSA infections are treated by
glycopeptides which cost less than beta-lactams in our
country. Astagneau et al reported that the daily antibiotic
cost of multi-resistant bacterial infections such as multi-
resistant P. aeruginosa infections, was 20% higher than
susceptible infections, but the daily antibiotic cost per
infected patient for MRSA infections was not higher than
for susceptible strain infections [11].
Expensive antibiotics, such as piperacillin-tazobactam,
carbapenems, cefepime, ciprofloxacin, teicoplanin were
prescribed more commonly than the cheaper agents such
as ampicillin-sulbactam, ceftriaxone or ofloxacin in our
ICUs. These expensive antibiotics were mainly prescribed
for resistant and severe gram-negative nosocomial infec-
tions, such as ventilator-associated pneumonia and post-
neurosurgical meningitis in ICU. Physicians may be
forced to choose empirical antibiotic therapy with broad
spectrum antimicrobials by increasing bacterial multi-
resistance.
In conclusion, mean daily antibiotic cost was found
$89,64 per nosocomial infection in our ICUs and nosoco-
mial pneumonia had the highest daily antibiotic cost per
infected patient. It is clear that cost of antibiotic therapy of
nosocomial infections is an important part of extra cost
attributable to nosocomial infection. Approximately one
third of nosocomial infections are preventable by full
implementation of the current infection control guideline
recommendations [17]. Each institution should develope
empirical antibiotic guidelines according to its own local
nosocomial infections data. Infection control measures,
such as education of health care workers regarding antimi-
crobial agents and resistance; isolation of patients infected
with multi-resistant organisms, should be implemented
to reduce infections and expensive antibiotic
prescriptions.
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